172 related articles for article (PubMed ID: 24301498)
1. [Early use of biological agents after first DMARD in rheumatoid arthritis - no].
Keyßer G
Dtsch Med Wochenschr; 2013 Dec; 138(50):2620. PubMed ID: 24301498
[No Abstract] [Full Text] [Related]
2. [Early use of biological agents after first DMARD in rheumatoid arthritis - no].
Thomann U
Dtsch Med Wochenschr; 2013 Dec; 138(50):2620. PubMed ID: 24301497
[No Abstract] [Full Text] [Related]
3. [Early use of biological agents after first DMARD in rheumatoid arthritis--no].
Keyßer G
Dtsch Med Wochenschr; 2013 Sep; 138(37):1851. PubMed ID: 24006169
[No Abstract] [Full Text] [Related]
4. Drugs for rheumatoid arthritis.
Med Lett Drugs Ther; 2014 Dec; 56(1458):127-32. PubMed ID: 25519024
[No Abstract] [Full Text] [Related]
5. The safety of biological medicines for rheumatoid arthritis.
Papadopoulos I; Demetzos C; Markantoni-Kyroudi S; Souliotis K
Adv Exp Med Biol; 2015; 822():209-10. PubMed ID: 25416994
[No Abstract] [Full Text] [Related]
6. [Against parenteral gold therapy in rheumatoid arthritis].
Kellner H
Dtsch Med Wochenschr; 2011 Aug; 136(33):1677. PubMed ID: 21833892
[No Abstract] [Full Text] [Related]
7. Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.
Pavelka K; Akkoç N; Al-Maini M; Zerbini CAF; Karateev DE; Nasonov EL; Rahman MU; Pedersen R; Dinh A; Shen Q; Vasilescu R; Kotak S; Mahgoub E; Vlahos B
Rheumatol Int; 2017 Sep; 37(9):1469-1479. PubMed ID: 28597306
[TBL] [Abstract][Full Text] [Related]
8. How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers.
Chatzidionysiou K; Delcoigne B; Frisell T; Hetland ML; Glintborg B; Dreyer L; Cordtz R; Zobbe K; Nordström D; Trokovic N; Aaltonen K; Provan SA; Grondal G; Gudbjornsson B; Askling J
RMD Open; 2020 Sep; 6(2):. PubMed ID: 32900882
[No Abstract] [Full Text] [Related]
9. Current concepts in the management of rheumatoid arthritis.
Tanaka Y
Korean J Intern Med; 2016 Mar; 31(2):210-8. PubMed ID: 26932398
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic Therapies for Rheumatologic and Autoimmune Conditions.
Bays AM; Gardner G
Med Clin North Am; 2016 Jul; 100(4):719-31. PubMed ID: 27235612
[TBL] [Abstract][Full Text] [Related]
11. Abandoned therapies and unpublished trials in rheumatoid arthritis.
Keystone EC
Curr Opin Rheumatol; 2003 May; 15(3):253-8. PubMed ID: 12707578
[TBL] [Abstract][Full Text] [Related]
12. [Early use of biological agents after first DMARD in rheumatoid arthritis--yes].
Detert J
Dtsch Med Wochenschr; 2013 Sep; 138(37):1850. PubMed ID: 24006168
[No Abstract] [Full Text] [Related]
13. Safety of Biologic and Nonbiologic Disease-modifying Antirheumatic Drug Therapy in Veterans with Rheumatoid Arthritis and Hepatitis C Virus Infection.
Burton MJ; Curtis JR; Yang S; Chen L; Singh JA; Mikuls TR; Winthrop KL; Baddley JW
J Rheumatol; 2017 May; 44(5):565-570. PubMed ID: 28250142
[TBL] [Abstract][Full Text] [Related]
14. The when and how of biologic agent withdrawal in rheumatoid arthritis: learning from large randomised controlled trials.
Kavanaugh A; Smolen JS
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S19-21. PubMed ID: 24129131
[TBL] [Abstract][Full Text] [Related]
15. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis.
Holroyd CR; Seth R; Bukhari M; Malaviya A; Holmes C; Curtis E; Chan C; Yusuf MA; Litwic A; Smolen S; Topliffe J; Bennett S; Humphreys J; Green M; Ledingham J
Rheumatology (Oxford); 2019 Feb; 58(2):e3-e42. PubMed ID: 30137552
[No Abstract] [Full Text] [Related]
16. Why subcutaneous methotrexate should be a prerequisite to biologic use in patients with rheumatoid arthritis.
Koduri GM; Mukhtyar C
Rheumatology (Oxford); 2019 Apr; 58(4):559-560. PubMed ID: 29672739
[No Abstract] [Full Text] [Related]
17. Necessity of TNF-alpha inhibitor discontinuation in rheumatoid arthritis is predicted by smoking and number of previously used biological DMARDs.
Cuppen BV; Jacobs JW; Ter Borg EJ; Marijnissen AC; Bijlsma JW; Lafeber FP; van Laar JM;
Clin Exp Rheumatol; 2017; 35(2):221-228. PubMed ID: 27749223
[TBL] [Abstract][Full Text] [Related]
18. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis-Executive summary.
Holroyd CR; Seth R; Bukhari M; Malaviya A; Holmes C; Curtis E; Chan C; Yusuf MA; Litwic A; Smolen S; Topliffe J; Bennett S; Humphreys J; Green M; Ledingham J
Rheumatology (Oxford); 2019 Feb; 58(2):220-226. PubMed ID: 30137623
[No Abstract] [Full Text] [Related]
19. Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry.
Narongroeknawin P; Chevaisrakul P; Kasitanon N; Kitumnuaypong T; Mahakkanukrauh A; Siripaitoon B; Katchamart W;
Int J Rheum Dis; 2018 Jan; 21(1):170-178. PubMed ID: 28737837
[TBL] [Abstract][Full Text] [Related]
20. The role of low-dose glucocorticoids for rheumatoid arthritis in the biologic era.
Caporali R; Scirè CA; Todoerti M; Montecucco C
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S9-13. PubMed ID: 24129129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
